Rémy Luthringer

Rémy is the CEO of Minerva Neurosciences (Nasdaq: NERV) and was formerly an advisor to Index Ventures, Chief Medical Officer of the Index Life VI biotech fund raised by Index Ventures in 2012, and a member of the Scientific Advisory Board of the fund. He has participated in several investments and more particularly has had an active advisory role in several companies including the following: Funxional Therapeutics, Linguaflex and V-Watch. Prior to joining Index, he was the President and CEO of the Forenap group, a research organization focused in neurosciences and drug development based in France.

Rémy is the author of around 50 publications, has been involved in the development of more than 150 central nervous system (CNS) molecules and has carried out more than 700 clinical trials.